ECM2026, 14-17 June 2026, Copenhagen, DenmarkDear colleagues,
We are pleased to welcome you to ECM2026.
We meet at a time of significant progress for extracellular matrix research (ECM) research. In recent years, the field has moved from basic biological insights to therapeutic innovation. We now see the first ECM targeting therapies reaching patients – with antifibrotic treatments emerging in liver fibrosis, and additional therapies in late development for lung fibrosis. This marks a transition from concept to clinic – one that we are proud to celebrate together.
The progress is driven by a growing recognition of the role of fibroblasts and ECM dynamics across organs. Fibrogenesis is involved in approximately 40% of deaths in the Western world—yet remain underrepresented in current therapeutic strategies. ECM2026 provides a platform to address this gap.
To do so, we must identify both common and organ-specific mechanisms of fibrosis, including the interplay between fibro-inflammation and systemic, multi-organ disease. It is clear that meaningful innovation only can be achieved through collaboration across disciplines, institutions, and sectors.
The spirit of ECM2026 is captured with the slogan—Fresh ideas, bright science, next-generation therapies—reflecting this ambition and the translational potential of our field.
The success of previous meetings, including ECM2024 with more than 450 participants, 180 abstracts, and 80 oral presentations, is a testament to the strength of this community. We look forward to continuing that momentum together.
Thank you for being part of ECM2026. We look forward to an inspiring and impactful meeting.
Sincerely,
Morten Karsdal, PhD, Professor
Chair ECM2026
